Search
obiltoxaximab (Anthim)
Indications:
- treatment of inhalation anthrax in combination with antibacterial agents
- prevention of inhalational anthrax when alternative therapies are not available or not appropriate
Dosage:
- IV infusion
Adverse effects:
- headache
- pruritus
- upper respiratory tract infections
- cough
- nasal congestion
- hives
- bruising
- swelling
- pain at the infusion site
- hypersensitivity, anaphylaxis
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
antibacterial agent
References
- FDA News. March 21, 2016
FDA approves new treatment for inhalation anthrax.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491470.htm